Perdagangan Merck KGaA - EUR - MRKd CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | 0.70 | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.024161% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | -0.020283% | ||||||||
Waktu biaya inap | 22:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | EUR | ||||||||
Margin | 20% | ||||||||
Bursa efek | Germany | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
Merck KGaA ESG Risk Ratings
High Medium Low Negligible
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Key Stats
Prev. Close* | 181.8 |
Open* | 180.45 |
1-Year Change* | -7.93% |
Day's Range* | 180.2 - 184.7 |
52 wk Range | 153.10-202.80 |
Average Volume (10 days) | 285.14K |
Average Volume (3 months) | 6.02M |
Market Cap | 23.59B |
P/E Ratio | 22.87 |
Shares Outstanding | 434.78M |
Revenue | 21.79B |
EPS | 7.98 |
Dividend (Yield %) | 1.0137 |
Beta | 0.58 |
Next Earnings Date | Mar 2, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 1, 2023 | 181.80 | -7.00 | -3.71% | 188.80 | 188.85 | 181.10 |
Jan 31, 2023 | 190.75 | -2.60 | -1.34% | 193.35 | 193.55 | 189.65 |
Jan 30, 2023 | 193.60 | 4.10 | 2.16% | 189.50 | 194.05 | 188.95 |
Jan 27, 2023 | 190.05 | -1.40 | -0.73% | 191.45 | 191.90 | 189.55 |
Jan 26, 2023 | 192.30 | -1.90 | -0.98% | 194.20 | 195.45 | 192.30 |
Jan 25, 2023 | 190.45 | 1.65 | 0.87% | 188.80 | 191.00 | 187.15 |
Jan 24, 2023 | 189.45 | -2.55 | -1.33% | 192.00 | 192.75 | 188.80 |
Jan 23, 2023 | 192.55 | 3.30 | 1.74% | 189.25 | 193.05 | 188.45 |
Jan 20, 2023 | 186.55 | -1.80 | -0.96% | 188.35 | 191.20 | 186.50 |
Jan 19, 2023 | 189.35 | -1.50 | -0.79% | 190.85 | 191.00 | 186.80 |
Jan 18, 2023 | 192.35 | -3.95 | -2.01% | 196.30 | 196.40 | 192.15 |
Jan 17, 2023 | 196.00 | -2.70 | -1.36% | 198.70 | 198.75 | 195.40 |
Jan 16, 2023 | 199.20 | 1.15 | 0.58% | 198.05 | 200.00 | 197.85 |
Jan 13, 2023 | 197.65 | 2.45 | 1.26% | 195.20 | 197.75 | 193.15 |
Jan 12, 2023 | 196.75 | -3.15 | -1.58% | 199.90 | 200.30 | 192.85 |
Jan 11, 2023 | 200.70 | 6.95 | 3.59% | 193.75 | 202.20 | 193.55 |
Jan 10, 2023 | 192.00 | 2.40 | 1.27% | 189.60 | 192.60 | 189.00 |
Jan 9, 2023 | 193.55 | 5.00 | 2.65% | 188.55 | 193.60 | 187.40 |
Jan 6, 2023 | 186.95 | 1.10 | 0.59% | 185.85 | 187.25 | 183.70 |
Jan 5, 2023 | 184.80 | -4.45 | -2.35% | 189.25 | 189.40 | 184.55 |
Merck KGaA - EUR Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 15024 | 14517 | 14836 | 16152 | 17534 | 19687 |
Revenue | 15024 | 14517 | 14836 | 16152 | 17534 | 19687 |
Cost of Revenue, Total | 5201 | 5071 | 5342 | 5951 | 6782 | 7325 |
Gross Profit | 9823 | 9446 | 9494 | 10201 | 10752 | 12362 |
Total Operating Expense | 12543 | 12094 | 13109 | 14032 | 14549 | 15508 |
Selling/General/Admin. Expenses, Total | 4409 | 4234 | 4256 | 4686 | 4600 | 4855 |
Research & Development | 1972 | 2102 | 2220 | 2239 | 2262 | 2400 |
Depreciation / Amortization | 1036 | 1020 | 979 | 923 | 636 | 589 |
Interest Expense (Income) - Net Operating | 57 | 3 | 62 | 1 | ||
Unusual Expense (Income) | -46 | -26 | 339 | 389 | 85 | 184 |
Other Operating Expenses, Total | -86 | -310 | -89 | -156 | 184 | 154 |
Operating Income | 2481 | 2423 | 1727 | 2120 | 2985 | 4179 |
Interest Income (Expense), Net Non-Operating | -274 | -243 | -209 | -338 | -350 | -255 |
Other, Net | -53 | -51 | -57 | -47 | -5 | 0 |
Net Income Before Taxes | 2154 | 2129 | 1461 | 1735 | 2630 | 3924 |
Net Income After Taxes | 1633 | 2557 | 1093 | 1295 | 1993 | 3065 |
Minority Interest | -4 | -10 | -22 | -3 | -7 | -10 |
Net Income Before Extra. Items | 1629 | 2547 | 1071 | 1292 | 1986 | 3055 |
Total Extraordinary Items | 0 | 57 | 2303 | 28 | 0 | |
Net Income | 1629 | 2604 | 3374 | 1320 | 1986 | 3055 |
Income Available to Common Excl. Extra. Items | 1629 | 2548 | 1071 | 1292 | 1987 | 3055 |
Income Available to Common Incl. Extra. Items | 1629 | 2605 | 3374 | 1320 | 1987 | 3055 |
Diluted Net Income | 1629 | 2605 | 3374 | 1320 | 1987 | 3055 |
Diluted Weighted Average Shares | 434.778 | 434.778 | 434.794 | 434.211 | 434.792 | 434.566 |
Diluted EPS Excluding Extraordinary Items | 3.74674 | 5.86046 | 2.46324 | 2.97552 | 4.57 | 7.03 |
Dividends per Share - Common Stock Primary Issue | 1.2 | 1.25 | 1.25 | 1.3 | 1.4 | 1.85 |
Diluted Normalized EPS | 3.66653 | 5.91727 | 3.04653 | 3.6442 | 4.71815 | 7.36072 |
Total Adjustments to Net Income | 1 | 0 | 1 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 4631 | 4870 | 4973 | 5213 | 5198 |
Revenue | 4631 | 4870 | 4973 | 5213 | 5198 |
Cost of Revenue, Total | 1721 | 1813 | 1859 | 1959 | 1987 |
Gross Profit | 2910 | 3057 | 3114 | 3254 | 3211 |
Total Operating Expense | 3588 | 3821 | 3926 | 4174 | 4025 |
Selling/General/Admin. Expenses, Total | 1280 | 1342 | 1376 | 1546 | 1374 |
Research & Development | 574 | 585 | 660 | 590 | 586 |
Unusual Expense (Income) | 6 | 0 | -1 | -6 | 5 |
Other Operating Expenses, Total | 7 | 81 | 32 | 85 | 73 |
Operating Income | 1043 | 1049 | 1047 | 1039 | 1173 |
Interest Income (Expense), Net Non-Operating | -60 | -95 | -54 | -47 | -34 |
Other, Net | 1 | 1 | |||
Net Income Before Taxes | 984 | 955 | 993 | 992 | 1139 |
Net Income After Taxes | 748 | 747 | 764 | 806 | 884 |
Minority Interest | -1 | -2 | -3 | -4 | -3 |
Net Income Before Extra. Items | 747 | 745 | 761 | 802 | 881 |
Net Income | 747 | 745 | 761 | 802 | 881 |
Income Available to Common Excl. Extra. Items | 747 | 745 | 761 | 802 | 880 |
Income Available to Common Incl. Extra. Items | 747 | 745 | 761 | 802 | 880 |
Diluted Net Income | 747 | 745 | 761 | 802 | 880 |
Diluted Weighted Average Shares | 434.302 | 434.778 | 434.857 | 433.438 | 435.644 |
Diluted EPS Excluding Extraordinary Items | 1.72 | 1.71352 | 1.75 | 1.85032 | 2.02 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 1.85 | 0 |
Diluted Normalized EPS | 1.80927 | 1.90422 | 1.8827 | 1.80908 | 2.07345 |
Total Adjustments to Net Income | 0 | -1 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 7670 | 7455 | 9236 | 9003 | 9280 | 10982 |
Cash and Short Term Investments | 981 | 623 | 2199 | 598 | 1234 | 1685 |
Cash & Equivalents | 662 | 481 | 779 | 541 | 1109 | 1511 |
Short Term Investments | 319 | 142 | 1420 | 57 | 125 | 174 |
Total Receivables, Net | 3607 | 3707 | 3738 | 4233 | 3910 | 4345 |
Accounts Receivable - Trade, Net | 2888 | 2923 | 3278 | 3644 | 3390 | 3853 |
Total Inventory | 2609 | 2632 | 2764 | 3342 | 3294 | 3900 |
Prepaid Expenses | 276 | 338 | 435 | 493 | 519 | 570 |
Other Current Assets, Total | 197 | 155 | 100 | 337 | 323 | 482 |
Total Assets | 38258 | 35621 | 36888 | 43811 | 41796 | 45362 |
Property/Plant/Equipment, Total - Net | 4231 | 4512 | 4811 | 6213 | 6421 | 7217 |
Property/Plant/Equipment, Total - Gross | 9404 | 9853 | 10551 | 12561 | 13228 | 14810 |
Accumulated Depreciation, Total | -5172 | -5340 | -5740 | -6348 | -6808 | -7593 |
Goodwill, Net | 15015 | 13582 | 13764 | 17141 | 15959 | 17004 |
Intangibles, Net | 9980 | 8317 | 7237 | 9175 | 7653 | 7612 |
Long Term Investments | 191 | 419 | 1 | 3 | ||
Note Receivable - Long Term | 15 | 41 | 614 | 746 | 830 | 922 |
Other Long Term Assets, Total | 1156 | 1295 | 1226 | 1533 | 1652 | 1622 |
Total Current Liabilities | 9089 | 8635 | 8517 | 11842 | 9231 | 10432 |
Accounts Payable | 2048 | 2195 | 1766 | 2054 | 1768 | 2380 |
Accrued Expenses | 603 | 778 | 799 | 791 | 975 | 1204 |
Notes Payable/Short Term Debt | 1855 | 1173 | 982 | 2224 | 515 | 1434 |
Current Port. of LT Debt/Capital Leases | 1908 | 1590 | 1217 | 2307 | 1780 | 1062 |
Other Current Liabilities, Total | 2675 | 2899 | 3753 | 4466 | 4193 | 4352 |
Total Liabilities | 24269 | 21618 | 19688 | 25945 | 24850 | 24024 |
Total Long Term Debt | 8706 | 7947 | 6608 | 8588 | 9745 | 8270 |
Long Term Debt | 8706 | 7947 | 6608 | 8130 | 9418 | 7928 |
Deferred Income Tax | 2724 | 1489 | 1288 | 1828 | 1441 | 1411 |
Minority Interest | 61 | 63 | 33 | 48 | 71 | 78 |
Other Liabilities, Total | 3689 | 3484 | 3242 | 3639 | 4362 | 3833 |
Total Equity | 13989 | 14003 | 17200 | 17866 | 16946 | 21338 |
Preferred Stock - Non Redeemable, Net | 397 | 397 | 397 | 397 | 397 | 397 |
Common Stock | 168 | 168 | 168 | 168 | 168 | 168 |
Additional Paid-In Capital | 3814 | 3814 | 3814 | 3814 | 3814 | 3814 |
Retained Earnings (Accumulated Deficit) | 8049 | 9902 | 12532 | 13236 | 14556 | 16673 |
Other Equity, Total | 1561 | -278 | 289 | 251 | -1989 | 286 |
Total Liabilities & Shareholders’ Equity | 38258 | 35621 | 36888 | 43811 | 41796 | 45362 |
Total Common Shares Outstanding | 434.778 | 434.778 | 434.778 | 434.778 | 434.778 | 434.778 |
Capital Lease Obligations | 458 | 327 | 342 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 10617 | 10182 | 10315 | 10982 | 11085 |
Cash and Short Term Investments | 2298 | 1870 | 1665 | 2073 | 1445 |
Cash & Equivalents | 2238 | 1825 | 1523 | 1899 | 1339 |
Short Term Investments | 60 | 45 | 142 | 174 | 106 |
Total Receivables, Net | 4226 | 4124 | 4207 | 4345 | 4705 |
Accounts Receivable - Trade, Net | 3816 | 3771 | 3930 | 3853 | 4345 |
Total Inventory | 3462 | 3564 | 3760 | 3900 | 4143 |
Other Current Assets, Total | 631 | 624 | 683 | 664 | 792 |
Total Assets | 43891 | 43145 | 43836 | 45362 | 46235 |
Property/Plant/Equipment, Total - Net | 6552 | 6601 | 6761 | 7217 | 7303 |
Goodwill, Net | 16541 | 16347 | 16670 | 17004 | 17761 |
Intangibles, Net | 7765 | 7613 | 7628 | 7612 | 7549 |
Long Term Investments | 770 | 744 | 794 | 914 | 905 |
Note Receivable - Long Term | 38 | 39 | 39 | 35 | 35 |
Other Long Term Assets, Total | 1608 | 1619 | 1629 | 1598 | 1597 |
Total Current Liabilities | 10652 | 9820 | 9793 | 10432 | 10207 |
Accounts Payable | 1937 | 2107 | 2132 | 2380 | 2356 |
Accrued Expenses | 118 | 144 | 191 | 224 | 174 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 3347 | 3278 | 2770 | 2531 | 2345 |
Other Current Liabilities, Total | 5250 | 4291 | 4700 | 5297 | 5332 |
Total Liabilities | 24975 | 23852 | 23229 | 24024 | 23316 |
Total Long Term Debt | 9001 | 8721 | 8195 | 8270 | 8286 |
Long Term Debt | 9001 | 8721 | 8195 | 8270 | 8286 |
Deferred Income Tax | 1440 | 1401 | 1374 | 1411 | 1389 |
Minority Interest | 67 | 68 | 72 | 78 | 71 |
Other Liabilities, Total | 3815 | 3842 | 3795 | 3833 | 3363 |
Total Equity | 18916 | 19293 | 20607 | 21338 | 22919 |
Preferred Stock - Non Redeemable, Net | 397 | 397 | 397 | 397 | |
Common Stock | 168 | 168 | 168 | 168 | 565 |
Additional Paid-In Capital | 3814 | 3814 | 3814 | 3814 | 3814 |
Retained Earnings (Accumulated Deficit) | 15240 | 15799 | 16556 | 16673 | 18540 |
Other Equity, Total | -703 | -885 | -328 | 286 | |
Total Liabilities & Shareholders’ Equity | 43891 | 43145 | 43836 | 45362 | 46235 |
Total Common Shares Outstanding | 434.778 | 434.778 | 434.778 | 434.778 | 434.778 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 1633 | 2615 | 3396 | 1324 | 1994 | 3065 |
Cash From Operating Activities | 2510 | 2696 | 2219 | 2856 | 3477 | 4616 |
Cash From Operating Activities | 1934 | 1758 | 1812 | 1944 | 1938 | 1762 |
Non-Cash Items | -488 | -250 | -2523 | 149 | -59 | 62 |
Changes in Working Capital | -569 | -1427 | -466 | -561 | -396 | -273 |
Cash From Investing Activities | -503 | -1147 | 2191 | -6153 | -1340 | -1578 |
Capital Expenditures | -848 | -1311 | -1016 | -1021 | -1563 | -1421 |
Other Investing Cash Flow Items, Total | 345 | 164 | 3207 | -5132 | 223 | -157 |
Cash From Financing Activities | -1908 | -1870 | -2825 | 1902 | -1522 | -2504 |
Financing Cash Flow Items | -464 | -469 | -607 | -527 | -519 | -576 |
Total Cash Dividends Paid | -136 | -155 | -162 | -162 | -168 | -181 |
Issuance (Retirement) of Debt, Net | -1308 | -1246 | -2056 | 2591 | -835 | -1747 |
Foreign Exchange Effects | 8 | -30 | -5 | 5 | -40 | 9 |
Net Change in Cash | 107 | -351 | 1580 | -1390 | 575 | 543 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 748 | 1495 | 2258 | 3065 | 884 |
Cash From Operating Activities | 1216 | 2104 | 3571 | 4616 | 840 |
Cash From Operating Activities | 424 | 843 | 1287 | 1762 | 430 |
Non-Cash Items | 6 | 25 | 46 | 62 | -24 |
Changes in Working Capital | 38 | -259 | -20 | -273 | -450 |
Cash From Investing Activities | -346 | -587 | -1226 | -1578 | -1089 |
Capital Expenditures | -362 | -638 | -1155 | -1421 | -498 |
Other Investing Cash Flow Items, Total | 16 | 51 | -71 | -157 | -591 |
Cash From Financing Activities | 6 | -1054 | -2184 | -2504 | -315 |
Financing Cash Flow Items | -55 | -575 | -575 | -576 | -100 |
Total Cash Dividends Paid | 0 | -181 | -181 | -181 | 0 |
Issuance (Retirement) of Debt, Net | 61 | -298 | -1428 | -1747 | -215 |
Foreign Exchange Effects | 7 | 6 | 7 | 9 | 4 |
Net Change in Cash | 883 | 469 | 168 | 543 | -560 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.8422 | 8842949 | 0 | 2022-09-27 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 4.84 | 6255325 | 3997581 | 2022-09-27 | LOW |
Fidelity International | Investment Advisor | 3.0193 | 3902150 | 2587266 | 2022-09-19 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.9271 | 3783100 | -924069 | 2022-05-18 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 2.8682 | 3706864 | -407104 | 2022-12-14 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.808 | 3629168 | 3816 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.9688 | 2544567 | 38064 | 2021-12-31 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 1.849 | 2389642 | 1240 | 2022-12-31 | LOW |
FMR Investment Management (U.K.) Limited | Investment Advisor | 1.3005 | 1680776 | -5936 | 2022-12-31 | LOW |
Deka Investment GmbH | Investment Advisor/Hedge Fund | 1.1334 | 1464775 | -25955 | 2022-12-31 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.1038 | 1426605 | 15714 | 2022-12-31 | LOW |
Allianz Global Investors GmbH | Investment Advisor | 1.0531 | 1361000 | -42080 | 2022-11-30 | LOW |
Union Investment Privatfonds GmbH | Investment Advisor | 0.9614 | 1242564 | 560959 | 2022-09-30 | LOW |
Eleva Capital SAS | Investment Advisor | 0.8919 | 1152665 | 25800 | 2022-10-31 | HIGH |
MFS International Singapore Pte. Ltd | Investment Advisor | 0.8661 | 1119411 | -22611 | 2022-12-31 | LOW |
BNP Paribas Asset Management France SAS | Investment Advisor/Hedge Fund | 0.8255 | 1066840 | -1655 | 2022-12-31 | LOW |
Lazard Asset Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7951 | 1027640 | -25959 | 2022-12-31 | LOW |
Walter Scott & Partners Ltd. | Investment Advisor/Hedge Fund | 0.7723 | 998128 | 0 | 2022-12-31 | LOW |
J O Hambro Capital Management Limited | Investment Advisor/Hedge Fund | 0.7686 | 993311 | -119431 | 2022-09-30 | MED |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7637 | 986974 | -3296 | 2022-12-31 | LOW |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group +485000+
Trader
65000+
Klien aktif per bulan
$48000000+
Volume investasi per bulan
$28000000+
Coba sekarang Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Proprietary & Advanced Pharmaceuticals |
Frankfurter Str. 250
DARMSTADT
HESSEN 64293
DE
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 485.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com